Medtronic Converts 125 Million Patient Days of Data Into Personalized Insights That Improve Diabetes Management
June 10 2016 - 9:00AM
CareLink® Portfolio Updates, IBM
Watson Partnership Progress and New Strategic Alliances
Delivering Intelligent Data and Actionable
Information at ADA 2016
DUBLIN and NEW ORLEANS - June 10,
2016 - Delivering on its vision to transform care for the
millions currently living with diabetes through intelligent data,
Medtronic plc (NYSE:MDT) announced new product developments and
technology partnerships at the American Diabetes Association (ADA)
76th Scientific Sessions that will create meaningful insights for
providers and people with diabetes.
New CareLink® offerings and
advancement of the Medtronic partnership with IBM Watson Health
give doctors and their patients more actionable information,
enabling care that is more collaborative, consistent and effective.
In addition, the growing network of Medtronic partnerships combines
Medtronic diabetes expertise with capabilities expanding data
usefulness to provide more holistic diabetes solutions.
"Data, insights and analytics have been a
cornerstone for our diabetes strategy with CareLink, and we have
accumulated over 125 million patient days of data generated by our
devices, including continuous glucose monitoring (CGM) sensor
readings and insulin pump events," said Annette Brüls, president,
Diabetes Service and Solutions at Medtronic. "Through our advanced
CareLink portfolio and our expanded network of partnerships, we
present actionable insights to drive holistic diabetes care
solutions that offer greater freedom and better health to people
with diabetes."
Medtronic is introducing several breakthrough
solutions to improve and simplify diabetes management. These
solutions include a combination of CareLink advancements, data from
Medtronic devices and analytical capabilities of IBM Watson Health
as well as an expanded network of partners such as Nutrino and
Glooko.
CareLink Software - Delivering
More Information to Physicians and Their Patients
Medtronic continues to expand its CareLink portfolio, helping
physicians make confident treatment decisions and patients
understand more about managing their diabetes effectively.
CareLink Pro software, available for over a decade, is the highest
rated diabetes therapy management tool by healthcare
professionals.
- CareLink Pro Reports Now
Available to Patients: People with
diabetes now have access to seven current CareLink Pro reports
through CareLink Personal software, helping them have more
productive discussions with their doctors. When patients and their
doctors can view the same reports, diabetes care becomes more
collaborative and the information in the reports becomes more
actionable. Through Medtronic informatics and data analysis,
CareLink reports will continue to provide diabetes patients with
useful insights that can facilitate productive conversations about
treatment options and provide a big-picture perspective on an
individual's patterns and trends.
- New CareLink Pro Reports:
Showing for the first time at ADA, CareLink Pro software will
reveal four new reports that allow physicians to optimize patient
treatment. Through advanced informatics and analysis of glycemic
patterns, bolus behavior and basal rates, doctors can enhance
insulin pump therapy effectiveness, reduce burden and improve
overall care. Available later this summer, these reports will
offer doctors new insights on key diabetes management
challenges.
IBM Watson Health - Advancing Our
Partnership
Medtronic, along with its strategic technology partner IBM Watson
Health, have advanced to the final development stages and revealed
the name of a first-of-its-kind cognitive app - SugarWise(TM) with
Watson. Relating to a key diabetes concern (sugar) and the
intelligence we hope to deliver (wise), the Medtronic app is
designed to assist people in making daily diabetes management
easier and potentially more effective.
The first generation of the Medtronic SugarWise
app is expected to predict important patterns and trends - based on
retrospective analysis of patients' insulin, CGM and nutritional
data - to help people understand how their behavior affects their
glucose level in real time. In addition to further advance the
capabilities of future generations of the SugarWise app, the
companies have revealed new results on hypoglycemia prediction
using CareLink data from 10,000 anonymized patients which
demonstrated preliminary prediction accuracy of 75%-86% within a
two-to-four hour window1.
Nutrino - Data Partnership Lets
MiniMed® Connect Users
See the Impact of Food on Diabetes
Medtronic has also entered into a data partnership with Nutrino, a
technology-based platform focused on diet and nutrition. MiniMed
Connect customers will now have access to a new Nutrino app that
combines CGM data with Nutrino's science-based nutritional
insights. The new app, currently in beta testing, will use
Nutrino's proprietary technology to give users a FoodPrint(TM)
based on their daily food intake, activity, sleep and other
parameters affecting their glucose levels.
Glooko - First Mobile Health
Solution Compatible with Medtronic Pumps and Sensors
Glooko, a unified platform for diabetes management, now has
compatibility with Medtronic insulin pumps and sensors. This
integration gives Medtronic customers expanded options for
displaying and using their diabetes data. Glooko's integrated
solution optimizes workflows for both people with diabetes and
clinics to download data from Medtronic. As a part of the 'Glooko
Advise' decision support product line, Glooko also has the ability
to correlate insulin data with readings and biometrics data
collected from over 50 blood glucose meters and fitness devices.
They will demonstrate their integration at the ADA in booth
811.
About the Diabetes Group at
Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change
the way people manage diabetes. The company aims to transform
diabetes care by expanding access, integrating care and improving
outcomes, so people living with diabetes can enjoy greater freedom
and better health.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 85,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
1 Preliminary
research results - based on dataset in controlled environment -
Data on File
Contacts:
Pamela Reese
Public Relations
+1-818-576-3398
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
HUG#2019465
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024